Innoviva, INC 8-K filings

Innoviva, Inc. announced robust second quarter 2026 financial results, featuring significant year-over-year revenue growth and the launch of a new strategic healthcare asset.

Innoviva announces the resignations of two directors, Derek Small and Mark DiPaolo, and the subsequent appointment of Josephine Linden to its Board.

Innoviva, Inc. announced robust first-quarter 2026 financial results, showcasing significant year-over-year growth in net product sales and substantial value creation from its strategic healthcare asset portfolio.

Innoviva, Inc. held its Annual Meeting of Stockholders on May 4, 2026, where directors were elected, executive compensation was approved on an advisory basis, and Deloitte & Touche LLP was ratified as the independent auditor.

Innoviva, Inc. announced robust financial results for Q4 and full year 2025, driven by significant revenue growth, strong product sales, and the FDA approval of NUZOLVENCE.

Innoviva, Inc. announced robust third-quarter 2025 financial results, driven by strong product sales and royalty growth, alongside a new $125 million share repurchase program.

Innoviva reports robust second quarter 2025 financial results driven by strong royalty performance and significant growth in net product sales, alongside key regulatory milestones for its infectious disease pipeline.

Innoviva, Inc. held its annual meeting on May 19, 2025, where stockholders elected five directors, approved executive compensation on an advisory basis, and ratified the selection of Deloitte & Touche LLP as the independent auditor for fiscal year 2025.

Innoviva's Q1 2025 results show a strong royalty platform and growth in specialty therapeutics, despite a net loss due to unfavorable changes in investment values.

Innoviva announces positive fourth quarter and full year 2024 financial results, highlighting growth in royalty revenue and U.S. net product sales, along with the acquisition of U.S. commercialization rights to ZEVTERA.

Innoviva's Q3 2024 results show strong revenue growth, driven by a 6% increase in GSK royalties and a 68% surge in U.S. net product sales.

Innoviva's second quarter of 2024 saw strong performance with a 38% year-over-year growth in its marketed portfolio and significant royalty revenue.

Innoviva, Inc. held its annual stockholders meeting on June 17, 2024, where directors were elected, executive compensation was approved, and the company's independent auditor was ratified.

Innoviva's latest investor presentation showcases a diversified healthcare portfolio with a strong royalty business and growing specialty therapeutics platform.

Innoviva's first quarter 2024 results show a strong performance with increased royalty revenue, significant product sales growth, and positive pipeline developments.

Innoviva, Inc. has appointed Derek Small, a seasoned biopharmaceutical executive, to its Board of Directors, effective April 29, 2024.

Innoviva's Q4 2023 results show a significant increase in royalty revenue and net product sales, alongside key pipeline advancements and strategic investments.